This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Curis, Inc. Identifier:
First received: August 1, 2008
Last updated: November 17, 2011
Last verified: November 2011
This is a phase I, open-label, dose-escalation study of CUDC-101 in patients with advanced and refractory solid tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2(Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, including the maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of CUDC-101.

Condition Intervention Phase
Tumors Drug: CUDC-101 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors

Further study details as provided by Curis, Inc.:

Primary Outcome Measures:
  • To establish the maximum tolerated dose (MTD) for CUDC-101 and to assess the safety and tolerability of CUDC-101 in subjects with advanced and refractory solid tumors. [ Time Frame: Study treatment period ]

Secondary Outcome Measures:
  • To evaluate the efficacy of CUDC-101 in subjects with advanced and refractory solid tumors. [ Time Frame: Study treatment period ]
  • To assess the pharmacokinetics of CUDC-101 in this patient population. [ Time Frame: Study treatment period ]
  • To evaluate pharmacodynamic biomarkers of CUDC-101 activity. [ Time Frame: Study treatment period ]

Enrollment: 25
Study Start Date: August 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: CUDC-101
    Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with advanced, refractory solid tumors and a histopathologically confirmed diagnosis
  • Subjects must have no further standard of care options or have refused standard therapy
  • Measurable or evaluable disease
  • Age ≥ 18 years
  • ECOG performance < 2
  • Life expectancy ≥ 3 months
  • If female, neither pregnant or lactating
  • If of child bearing potential, must use adequate birth control
  • Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL;
  • Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60mL/min/1.73m2
  • Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver metastases, the AST/ALT may be ≤ 5x ULN
  • Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation
  • Serum magnesium and potassium within normal limits (may be supplement to achieve normal values)
  • Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg prednisone/day or its equivalent dose of steroids
  • Able to render informed consent and to follow protocol requirements.

Exclusion Criteria:

  • Anticancer therapy within 4 weeks of study entry. Prostate cancer subjects on LHRH hormonal therapy may be enrolled and continue on this therapy.
  • Use of investigational agent(s) within 30 days of study entry
  • History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  • The following are permitted but should be used with caution and other suitable agents used if possible:

    • Subjects receiving concomitant medications metabolized by CYP 3A4 and CYP 2D6
    • CYP3A4 inducers
    • CYP3A4 inhibitors
    • Warfarin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00728793

United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Curis, Inc.
Principal Investigator: Anthony Tolcher, M.D. START (South Texas Accelerated Research Therapeutics)
  More Information

Additional Information:
Responsible Party: Curis, Inc. Identifier: NCT00728793     History of Changes
Other Study ID Numbers: CUDC-101-101
Study First Received: August 1, 2008
Last Updated: November 17, 2011

Keywords provided by Curis, Inc.:
Advanced Solid Tumors
Dose-Escalation processed this record on September 25, 2017